Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
10.10
-0.07 (-0.69%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Precision BioSciences Revenue
Precision BioSciences had revenue of $17.58M in the quarter ending March 31, 2024, with 100.27% growth. This brings the company's revenue in the last twelve months to $57.53M, up 88.25% year-over-year. In the year 2023, Precision BioSciences had annual revenue of $48.73M with 94.15% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+88.25%
P/S Ratio
1.22
Revenue / Employee
$527,807
Employees
109
Market Cap
69.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Eagle Pharmaceuticals | 257.55M |
Burning Rock Biotech | 72.30M |
Theratechnologies | 60.71M |
Pro-Dex | 49.46M |
Gritstone bio | 15.65M |
Celularity | 14.79M |
InspireMD | 6.48M |
DTIL News
- 18 days ago - Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit - Business Wire
- 25 days ago - Precision BioSciences Announces its Addition to the Russell Microcap® Index - Business Wire
- 4 weeks ago - Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 - Business Wire
- 5 weeks ago - Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D. - Business Wire
- 7 weeks ago - Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress - Business Wire
- 2 months ago - Precision BioSciences to Participate in Upcoming June Investor Conferences - Business Wire
- 2 months ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire